BRD4 in particular has been identified as a key therapeutic target in AML based on an RNAi screen of epigenetic genes in an mixed lineage leukemia (MLL) fusion leukemia mouse model [1]. This evidence concerns the gene BRD4 and acute myeloid leukemia.